Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05557292 · ClinicalTrials.gov registry record · Phase 1
RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma
A Phase 1 study of Glioblastoma and Recurrent Glioblastoma, sponsored by Nicholas Butowski.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT05557292: Recruiting Phase 1 study of Glioblastoma and Recurrent Glioblastoma, sponsored by Nicholas Butowski.
NCT05557292 is a Phase 1 study of Glioblastoma and Recurrent Glioblastoma that is actively recruiting participants, run by Nicholas Butowski. The registered enrollment target is 48 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (56% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05557292, a Phase 1 study of Glioblastoma and Recurrent Glioblastoma, is actively recruiting participants, sponsored by Nicholas Butowski.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I/Ib trial tests the side effects, best dose, tolerability, and effectiveness of RMC-5552 in treating patients with glioblastoma that has come back (recurrent). RMC-5552 is a type of medicine called an mechanistic target of rapamycin (mTOR) inhibitor. These types of drugs prevent the formation of a specific group of proteins called mTOR. This protein controls cancer cell growth, and the study doctors believe stopping mTOR from forming may help to kill tumor cells.
Primary Outcome
MTD is defined as the maximal dose at which fewer than one-third of participants experience a dose-limiting toxicity (DLT).
Conditions Studied
Interventions
- DRUG RMC-5552
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2023-04-03 |
| Est. Completion | 2030-04-30 |
| Phase | Phase 1 |
What NCT05557292 shows while recruiting
NCT05557292 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (56% lower).
The record links to 2 conditions, with Glioblastoma appearing as the primary indexed condition, and to 1 intervention - of which RMC-5552 is the first listed.
NCT05557292 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05557292 about?
NCT05557292 is a clinical study titled "RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma". This phase I/Ib trial tests the side effects, best dose, tolerability, and effectiveness of RMC-5552 in treating patients with glioblastoma that has come back (recurrent). RMC-5552 is a type of medicine called an mechanistic target of rapamycin (mTOR) inhibitor. These types of drugs prevent the form...
What is the current status of trial NCT05557292?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2023-04-03. Estimated completion is 2030-04-30.
What conditions does trial NCT05557292 study?
This clinical trial studies the following conditions: Glioblastoma, Recurrent Glioblastoma.
What interventions are being tested in trial NCT05557292?
The interventions under investigation include: RMC-5552 (DRUG).
Who is sponsoring clinical trial NCT05557292?
This trial is sponsored by Nicholas Butowski, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05557292 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05557292's enrollment target sits among peer trials
48 90th of 199 higher than 106 of 199 other Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
RECRUITING · Phase 1
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
CUE-102 in Recurrent Glioblastoma
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI